Skip to main content
SpringerLink
Log in

Appropriate intervention strategies for weight gain induced by olanzapine: A randomized controlled study

  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Weight gain induced by antipsychotics is the second most frequently given reason for noncompliance with pharmacologic therapy; excessive sedative effects rank first, with extrapyramidal side effects ranking third. Frequently, weight gain leads to inconsistent pharmacologic treatment; this exposes patients to the risk of recurrent symptoms. In fact, one of the key contributors to good clinical outcomes in schizophrenic patients is compliance with pharmacologic treatment. The goals of this study were to evaluate weight gain in a group of patients treated with olanzapine, diet modifications, and moderate physical activity and to compare the findings with those from a second group of patients who were given only olanzapine treatment. For 8 wk, investigators followed 2 groups of patients suffering from schizophrenia and hypomania in bipolar disorder, according to the nosographic criteria ofThe Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). The first group (A) of 18 patients (9 female, 9 male) affected by manic episodes in bipolar disorder received olanzapine (10–20 mg/d), jogged lightly for 30 min 3 times a week, and complied with a diet that consisted of 500 kcal/d less than usual. The second group (B) of 10 patients (4 female, 6 male) with schizophrenia received only olanzapine (10–20 mg/d). All patients from both groups were weighed at the beginning of the observation period and weekly thereafter for 2 mo. After 2 mo of observation, group A showed a mean weight gain of 1.47 kg, whereas group B exhibited a mean weight gain of 3.5 kg; the difference between the 2 groups was almost 2 kg (P<.005). Group A showed a statistically significant reduction in weight gain compared with group B, clearly demonstrating the effectiveness of moderate physical activity and diet therapy in reducing weight gain in atypical antipsychotic treatment. Therefore, patient weight and body mass index must be monitored during the first weeks of antipsychotic treatment, with the goals of avoiding significant weight gain and treatment interruption.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Hardman JG, Limbird LE, Goodman Gilman A (eds.)Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 10th ed. New York, NY: McGraw-Hill; 2001.

    Google Scholar 

  2. Pijl H, Meinders E. Bodyweight change as an adverse effect of drug treatment.Drug Safety. 1996; 4:329–342.

    Article  Google Scholar 

  3. Sussman N, Ginsberg D. Effects of psychotropic drugs on weight.Psychiatr Ann. 1999;29:580–594.

    Google Scholar 

  4. Zinnerman U, Kraus T. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients.J Psychiatry Res. 2003;37:193–220.

    Article  Google Scholar 

  5. Vanina Y, Podolskaya A, Sedky K, et al. Body weight changes associated with psychopharmacology.Psychiatr Serv. 2002;53:842–847.

    Article  PubMed  Google Scholar 

  6. Aquila R, Emanuel M. Interventions for weight gain in adults treated with novel antipsychotics: primary care companion.J Clin Psychiatry. 2000;2:20–23.

    Google Scholar 

  7. Birt J. Management of weight gain associated with antipsychotics.Ann Clin Psychiatry. 2003; 15:49–58.

    Article  PubMed  Google Scholar 

  8. Pancheri P. Farmacoterapia psichiatrica. Masson, ed; 2003.

  9. Allison BD, Casey D. Antipsychotic-induced weight gain: a review of the literature.J Clin Psychiatry. 2001;62(suppl 7):22–31.

    PubMed  CAS  Google Scholar 

  10. Marder SR, Essock SM. Physical health monitoring of patients with schizophrenia.Am J Psychiatry. 2004;161:1334–1349.

    Article  PubMed  Google Scholar 

  11. Melkerson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics.Drugs. 2004;64:701–723.

    Article  Google Scholar 

  12. Kurzthaler I, Fleischacker W. The clinical implications of weight gain in schizophrenia.J Clin Psychiatry. 2001;62(suppl 7):32–37.

    PubMed  CAS  Google Scholar 

  13. LIGIO 1999 Linee Guida Italiane Obesità. Pendragon Edizioni Bologna.

  14. Blin O, Micallef J. Antipsychotic associated weight gain and clinical outcome parameters.J Clin Psychiatry. 2001;62(suppl 7):11–21.

    PubMed  CAS  Google Scholar 

  15. Taylor DM, McAskill R. Atypical antipsychotic and weight gain: a systematic review.Acta Psychiatr Scand. 2000;101:416–432.

    Article  PubMed  CAS  Google Scholar 

  16. Sussman N. Review of atypical antipsychotic and weight gain.J Clin Psychiatry. 2001;(suppl 23): 292–293.

  17. Malhotra S, McElroy S. Medical management of obesity associated with mental disorders.J Clin Psychiatry. 2002;63(suppl 4):32.

    Google Scholar 

  18. Milano W. Dismetabolismi in corso di trattamento con antipsicotici: obesità e sindrome metabolica. Masson, ed; 2005.

  19. Baptista T, Kin N, Beaulieu S. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.Pharmacopsychiatry. 2002;35:205–219.

    Article  PubMed  CAS  Google Scholar 

  20. Wirshing D. Adverse effects of atypical antipsychotics.J Clin Psychiatry. 2001;62(suppl 21):7.

    PubMed  CAS  Google Scholar 

  21. Kahn BB, Lier JS. Obesity and insulin resistance.J Clin Invest. 2000;106:473–481.

    Article  PubMed  CAS  Google Scholar 

  22. Henderson DC. Clinical experience with insulin resistance, diabetic ketoacidosis and type 2 diabetes mellitus in patients treated with atypical antipsychotics.J Clin Psychiatry. 2001; (suppl 27):10-14.

  23. Bluher S, Mantzoros CS. The role of leptin in regulating neuroendocrine function in humans.J Nutr. 2004;134:2469S-2474S.

    PubMed  Google Scholar 

  24. Monteleone P, Fabrazzo M, Tortorella A, May M. Pronounced, early increase in circulating leptin predicts lower weight gain during clozapine treatment.J Clin Psychopharmacol. 2002;22:424–426.

    Article  PubMed  CAS  Google Scholar 

  25. Monteleone P, Di Lieto A, Tortorella A, Maj M. Circulating leptin in patients with anorexia nervosa, bulimia nervosa or binge eating disorder: relationship to body weight, eating patterns, psychopathology and endocrine changes.Psychiatr Res. 2000;94:121–129.

    Article  CAS  Google Scholar 

  26. Kraus T, Haack M, Schuld A, Kuhn M, Uhr M, Pollmacher T. Body weight and leptin levels during treatment with antipsychotic drugs.Am J Psychiatry. 1999;156:312–314.

    PubMed  CAS  Google Scholar 

  27. Bromel T, Blum WF, Ziegler A, et al. Serum leptin levels increase rapidly after initiation of clozapine therapy.Mol Psychiatry. 1998;3:76–80.

    Article  PubMed  CAS  Google Scholar 

  28. Hagg S, Soderberg S, Olsson T, Mjorndal T. Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics.J Clin Psychiatry. 2001;62:843–848.

    Article  PubMed  CAS  Google Scholar 

  29. Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.J Clin Psychiatry. 2003;64:598–604.

    Article  PubMed  CAS  Google Scholar 

  30. Baptista T, Lacruz A, Silvera R, Mendoza S, Hernandez L. Endocrine and metabolic profile in the obesity associated with typical antipsychotic drug administration.Pharmacopsychiatry. 2001;34:223–231.

    PubMed  CAS  Google Scholar 

  31. Baptista T, Lacruz A. Endocrine and metabolic profile in obesity associated with typical antipsychotic drug-administration.Pharmacopsychiatry. 2001;34:223–231.

    PubMed  CAS  Google Scholar 

  32. Bjorntorp P. Regional obesity. In: Bjorntrop P, Brodoff BN (eds.)Obesity. Philadelphia, Pa: JB Lippincott; 1992:579–586.

    Google Scholar 

  33. Baptista T, Reyes D. Antipsychotic drugs and reproductive hormones: relationship to body weight regulation.Pharmacol Biochem Behav. 1999;62:409–417.

    Article  PubMed  CAS  Google Scholar 

  34. Baptista T, Alastre T, Contreras Q. Effects of the antipsychotic drugs sulpiride on reproductive hormones in healthy men: relationship with body weight regulation.Pharmacopsychiatry. 1997; 30:250–255.

    Article  PubMed  CAS  Google Scholar 

  35. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.Drugs. 2004;64:2291–2314.

    Article  PubMed  CAS  Google Scholar 

  36. Hester EK, Thrower MR. Current options in the management of olanzapine-associated weight gain.Ann Pharmacother. 2005;39:302–310.

    Article  PubMed  CAS  Google Scholar 

  37. Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management.Acta Psychiatr Scand. 1999;100:3–16.

    Article  PubMed  CAS  Google Scholar 

  38. Baptista T, Lacruz A, Meza T, Herandez L. Antipsychotic drugs and obesity: is prolactin involved?Can J Psychiatry. 2001;46:829–834.

    PubMed  CAS  Google Scholar 

  39. Mihara K, Kondo T, Suzuki A. Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene.Psychopharmacology. 2000;149:246–250.

    Article  PubMed  CAS  Google Scholar 

  40. Wang GJ, Volkow ND, Logan J, et al. Brain dopamine and obesity.Lancet. 2001;357:354–357.

    Article  PubMed  CAS  Google Scholar 

  41. National Institutes of Health, National Heart, Lung and Blood Institute.The Clinical Guidelines on Identification, Evaluation and Treatment of Overweight and Obesity in the Adult: The Evidence Report. Bethesda, Md: NHLBI; 1998. NIH Publication No. 98-4083.

    Google Scholar 

  42. Aquila R. Management of weight gain in patients with schizophrenia.J Clin Psychiatry. 2002; 63(suppl 4):33–36.

    PubMed  Google Scholar 

  43. Kurzthaler I, Flischacker W. The clinical implications of weight gain in schizophrenia. JClin Psychiatry. 2001;62(suppl 7):32–37.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mental Health Unit, District 44-ASL, Naples, Italy

    W. Milano MD, F. Grillo MD, A. Del Mastro MD, M. De Rosa MD, B. Sanseverino MD & C. Petrella MD

  2. Department of Pharmaceutical Sciences, University of Salerno, via Ponte Don Melillo, 84084, Fisciano (Salerno), Italy

    A. Capasso (Prof)

Authors
  1. W. Milano MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Grillo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Del Mastro MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. De Rosa MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. Sanseverino MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Petrella MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Capasso
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Milano, W., Grillo, F., Del Mastro, A. et al. Appropriate intervention strategies for weight gain induced by olanzapine: A randomized controlled study. Adv Therapy 24, 123–134 (2007). https://doi.org/10.1007/BF02850000

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02850000

Keywords

Search

Navigation